Market Introduction
Asia Pacific blood brain barrier technologies market is analyzed based countries such as China, Japan, India, Australia, South Korea, and the rest of Asia Pacific. The Asia Pacific region is expected to be the fastest-growing region among all other regions. The growth of the market in this region is expected to grow at a faster pace owing to factors such as large pool of patients, increasing awareness about neurodegenerative disorders, and advancement in technology coupled with growing R&D in developing countries in the Asia Pacific region. Additionally, developing healthcare infrastructure and increasing investments to boost the manufacturing capacities are projected to drive the Asia Pacific blood brain barrier technologies market during the forecast period.
As of September 2021, COVID-19 cases reached 56.5 million in Asia Pacific, according to the United Nations Office for the Coordination of Humanitarian Affairs (UNOCHA). COVID-19 also attacks the brain, which may result in a global or focal neurologic manifestation, according to few studies carried out in Asia. It has been reported that COVID-19 infection can also show several neurologic manifestations, such as ageusia, anosmia, or dysgeusia, and causes neurologic disorders such as stroke, encephalopathy, Guillain-Barre syndrome, and many more. Emerging evidence has revealed that SARS-CoV-2 can affect the central nervous system (CNS) in addition to the respiratory system. Scientists detected SARS-CoV-2 RNA in multiple organs, including post-mortem brain tissue of patients with COVID-19. A recent study of COVID-19 patients following an autopsy showed that SARS-CoV-2 was present in cortical neurons. In addition, the results from human brain organoids also illustrated the neuroinvasion capability of SARS-CoV-2. Together, these data provide evidence for SARS-CoV-2 infection in the human CNS, but how the virus invades the brain is still undiscovered. In few research studies, it has been observed the spike protein of the SARS-CoV-2 virus also crosses the blood brain barrier in several models. As a result, the blood-brain barrier technologies market in the region has seen significant expansion due to the COVID-19 impact.
Market Overview and Dynamics
The blood brain barrier technologies market in Asia Pacific is expected to grow from US$ 221.98 million in 2021 to US$ 1,123.04 million by 2028; it is estimated to grow at a CAGR of 26.1% from 2021 to 2028. Neurological disorders such as epilepsy and seizures, Parkinson's disease, dementia, autism, Alzheimer's disease, brain tumors, and cerebral palsy, among others affect the brain and nerves of the human body. Epilepsy is a noncommunicable chronic brain disease that affects people of all ages. According to the World Health Organization (WHO), around 50 million people worldwide have epilepsy, making it one of the most common neurological diseases in the world. Almost 80% of people with epilepsy live in low- and middle-income countries. The same source estimates that up to 70% of people with epilepsy could live seizure-free with proper diagnosis and treatment. Dementia is currently the seventh leading cause of death among all diseases and one of the leading causes of disability and addiction in older people worldwide. According to the WHO, more than 55 million people live with dementia worldwide, and there are nearly 10 million new cases every year. Dementia is caused by a variety of diseases and injuries that primarily or secondarily affect the brain. Alzheimer's disease is the most common form of dementia and may contribute to 60–70% of cases. Thus, the growing prevalence of neurological disorders demands advanced blood-brain barrier technologies for the treatment is expected to drive the market during the forecast period.
Key Market Segments
In terms of technology, the increasing permeability segment accounted for the largest share of the Asia Pacific blood brain barrier technologies market in 2021. In terms of application, the parkinson’s disease segment accounted for the largest share of the Asia Pacific blood brain barrier technologies market in 2021.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the blood brain barrier technologies market in Asia Pacific are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Teva Pharmaceutical Industries Ltd.; F. Hoffmann-La Roche Ltd.; Eli Lilly and Company; Bristol-Myers Squibb Company; Pfizer, Inc.; Johnson & Johnson Services, Inc.; and JCR Pharmaceuticals Co., Ltd. among others.
Reasons to buy report
Asia Pacific Blood Brain Barrier Technologies Market Segmentation
Asia Pacific Blood Brain Barrier Technologies Market – By Technology
Asia Pacific Blood Brain Barrier Technologies Market – By Application
Asia Pacific Blood Brain Barrier Technologies Market – By Country
Asia Pacific Blood Brain Barrier Technologies Market – Companies Mentioned
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 221.98 Million |
| Market Size by 2028 | US$ 1,123.04 Million |
| CAGR (2021 - 2028) | 26.1% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Technology
|
|
Regions and Countries Covered
|
|
| Asia-Pacific | China, India, Japan, Australia, Rest of Asia-Pacific |
| Market leaders and key company profiles |
|
The Asia Pacific Blood Brain Barrier Technologies Market is valued at US$ 221.98 Million in 2021, it is projected to reach US$ 1,123.04 Million by 2028.
As per our report Asia Pacific Blood Brain Barrier Technologies Market, the market size is valued at US$ 221.98 Million in 2021, projecting it to reach US$ 1,123.04 Million by 2028. This translates to a CAGR of approximately 26.1% during the forecast period.
The Asia Pacific Blood Brain Barrier Technologies Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Blood Brain Barrier Technologies Market report:
The Asia Pacific Blood Brain Barrier Technologies Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific Blood Brain Barrier Technologies Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific Blood Brain Barrier Technologies Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+1 646 791 7070
sales@businessmarketinsights.com
Get Free Sample For Asia Pacific Blood Brain Barrier Technologies Market
